Ashtari Fereshteh, Toghianifar Nafiseh, Zarkesh-Esfahani Sayyed Hamid, Mansourian Marjan
Department of Neurology, Isfahan University of Medical Sciences, Isfahan, Iran.
Neuroimmunomodulation. 2015;22(6):400-4. doi: 10.1159/000439278. Epub 2015 Sep 25.
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system. Vitamin D has been related to the prevention of MS and to modulating its course. Recent studies have shown the safety of high-dose vitamin D in MS.
This study compared the effects of high-dose vitamin D on interleukin 10 (IL-10) levels in MS patients in a double-blind, randomized clinical trial.
Ninety-four patients with relapsing remitting MS (RRMS) were randomized into a treatment and a placebo group. Both groups received conventional MS treatment. The intervention group received 50,000 IU of vitamin D every 5 days for 3 months. IL-10 was measured at baseline and after 3 months.
Serum levels of IL-10 were (median ± IQR): 12.58 ± 11.97 and 10.97 ± 9.97 pg/ml in the intervention and placebo groups, respectively, at baseline (p = 0.161); after 3 months, these levels were 13.76 ± 18.95 and 11.31 ± 19.63 pg/ml, respectively (p = 0.158). The IL-10 level increased significantly after receiving high-dose vitamin D for 3 months (β = 0.737, p = 0.015 and R2 = 0.91).
IL-10 levels increased significantly in RRMS patients after taking high-dose vitamin D3 for 3 months. High-dose vitamin D might be useful in promoting an anti-inflammatory state in RRMS patients.
多发性硬化症（MS）是一种中枢神经系统的慢性脱髓鞘疾病。维生素D与MS的预防及其病程调节有关。最近的研究表明高剂量维生素D在MS中的安全性。
本研究在一项双盲、随机临床试验中比较了高剂量维生素D对MS患者白细胞介素10（IL-10）水平的影响。
94例复发缓解型MS（RRMS）患者被随机分为治疗组和安慰剂组。两组均接受常规MS治疗。干预组每5天接受50000 IU维生素D，持续3个月。在基线和3个月后测量IL-10。
干预组和安慰剂组在基线时IL-10的血清水平（中位数±四分位数间距）分别为12.58±11.97和10.97±9.97 pg/ml（p = 0.161）；3个月后，这些水平分别为13.76±18.95和11.31±19.63 pg/ml（p = 0.158）。接受高剂量维生素D 3个月后，IL-10水平显著升高（β = 0.737，p = 0.015，R2 = 0.91）。
RRMS患者服用高剂量维生素D3 3个月后，IL-10水平显著升高。高剂量维生素D可能有助于促进RRMS患者的抗炎状态。
